A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study). 12-Month Data: Report 2

Ophthalmology

Volumn 117, Issue 6, 2010, Pages

  Michaelides, Michel ^a,b   Kaines, Andrew ^a   Hamilton, Robin D ^a   Fraser Bell, Samantha ^a   Rajendram, Ranjan ^a,b   Quhill, Fahd ^a   Boos, Christopher J ^c   Xing, Wen ^a   Egan, Catherine ^a   Peto, Tunde ^a   Bunce, Catey ^a   Leslie, R David ^d   Hykin, Philip G ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; ANEMIA; ANGINA PECTORIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG INDUCED DISEASE; ENDOPHTHALMITIS; EPIPHORA; EYE DISEASE; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYE REDNESS; FALLING; FEMALE; FLOATER; FOOT ULCER; GASTROENTERITIS; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; INTERMITTENT CLAUDICATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR INFLAMMATION; INTRAOCULAR PRESSURE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; PERIFOVEAL CAPILLARY LOSS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RHEUMATIC POLYMYALGIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VITREOUS HEMORRHAGE; VOMITING; WRIST FRACTURE;

EID: 77952889192     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.03.045     Document Type: Article

References (30)

1. Bunce C., and Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. Eye (Lond) 22 (2008) 905-911
2. Paulus Y.M., and Gariano R.F. Diabetic retinopathy: a growing concern in an aging population. Geriatrics 64 (2009) 16-20
3. Deshpande A.D., Harris-Hayes M., and Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 88 (2008) 1254-1264
4. Klein R., Knudtson M.D., Lee K.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 116 (2009) 497-503
5. Diabetes ControlComplications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
7. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985) 1796-1806
8. Bhagat N., Grigorian R.A., Tutela A., and Zarbin M.A. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 54 (2009) 1-32
9. Fraser-Bell S., Kaines A., and Hykin P.G. Update on treatments for diabetic macular edema. Curr Opin Ophthalmol 19 (2008) 185-189
10. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115 (2008) 1447-1449
11. Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127 (2009) 245-251
12. Ockrim Z.K., Sivaprasad S., Falk S., et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol 92 (2008) 795-799
13. PKC-DRS2 Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113 (2006) 2221-2230
14. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 125 (2007) 318-324
15. Davis M.D., Sheetz M.J., Aiello L.P., et al., PKC-DRS2 Study Group. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci 50 (2009) 1-4
16. Chun D.W., Heier J.S., Topping T.M., et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113 (2006) 1706-1712
17. Nguyen Q.D., Shah S.M., Heier J.S., et al., READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 116 (2009) 2175-2181
18. Chung E.J., Roh M.I., Kwon O.W., and Koh H.J. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 28 (2008) 957-963
19. Arevalo J.F., Sanchez J.G., Wu L., et al., Pan-American Collaborative Retina Study Group (PACORES). Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 116 (2009) 1488-1497
20. Haritoglou C., Kook D., Neubauer A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26 (2006) 999-1005
21. Kook D., Wolf A., Kreutzer T., et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 28 (2008) 1053-1060
22. Soheilian M., Ramezani A., Bijanzadeh B., et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 27 (2007) 1187-1195
23. Soheilian M., Ramezani A., Obudi A., et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116 (2009) 1142-1150
24. Michaelides M., Fraser-Bell S., Hamilton R., et al. Macular perfusion determined by FFA at the four month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study). Report 1. Retina 30 (2010) 781-786
25. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms: ETDRS report number 11. Ophthalmology 98 suppl (1991) 807-822
26. Maturi R.K., Bleau L.A., and Wilson D.L. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26 (2006) 270-274
27. Iriyama A., Chen Y.N., Tamaki Y., and Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 91 (2007) 1230-1233
28. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 125 (2007) 469-480
29. Schachat A.P. A new look at an old treatment for diabetic macular edema. Ophthalmology 115 (2008) 1445-1446
30. Gangnon R.E., Davis M.D., Hubbard L.D., et al., Early Treatment Diabetic Retinopathy Study Research Group. A severity scale for diabetic macular edema developed from ETDRS data. Invest Ophthalmol Vis Sci 49 (2008) 5041-5047